BPC-157 is administered as a subcutaneous injection (a shallow, small-needle injection into fatty tissue, similar to an insulin injection)
International shipping isn't offered at this time due to customs and regulatory complexity around research compounds
Genetic mutation or disruption of the insulin receptor ( Insr ) has been shown to cause insulin resistance and T2DM in both humans and mice 3,4
Clinical practice and Perfect Bs protocol use a 3-month cycle: a loading phase, a maintenance phase, and a taper, followed by a 2-month break before reassessment
Lets see if I can convince you
Healthcare professionals can then assess whether symptoms represent expected therapeutic effects, require symptomatic management, or indicate a need to modify the treatment regimen